Business Wire

  1. Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery 4/2/2025

    Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle.

  2. MultiOmic Health And Alloy Therapeutics Collaborate To Discover And Develop Renal Tissue-Targeting Drugs 4/2/2025

    MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine discovery company focused on chronic multifactorial diseases, and Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced they have signed a Memorandum of Understanding to jointly discover and develop first-in-class renal tissue-targeting drugs.

  3. Japan Tobacco And D-Wave Announce Quantum Proof-Of-Concept Outperforms Classical Results For LLM Training In Drug Discovery 3/31/2025

    D-Wave Quantum Inc. (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) today announced the completion of a joint proof-of-concept project that used quantum computing technology and artificial intelligence (AI) in the drug discovery process.

  4. FDA Approves Qfitlia (Fitusiran), The First siRNA (RNAi Therapeutic) For The Treatment Of Hemophilia A Or B 3/28/2025

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.

  5. Redwire Awarded NASA Contract To Expand Pharmaceutical Drug Development In Space For Future Commercialization 3/25/2025

    Redwire Corporation, a leader in space infrastructure for the next-generation space economy, has been awarded a NASA contract to launch four additional pharmaceutical drug investigations to the International Space Station using the company’s innovative Pharmaceutical In-space Laboratory (PIL-BOX).

  6. SOLVE FSHD Announces Strategic Collaboration With Transcripta Bio To Advance Drug Discovery For FSHD 3/25/2025

    SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company.

  7. ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation For RCT2100 For The Treatment Of Cystic Fibrosis 3/25/2025

    ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT2100, a novel, investigational mRNA therapy being developed to treat cystic fibrosis (CF).

  8. Charles River And Valo Health Identify A Potential Therapeutic For Lupus Using Logica, An AI-Powered Drug Discovery Platform 3/25/2025

    Charles River Laboratories International, Inc. and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need.

  9. Sapio Sciences Makes AI-Native Drug Discovery Seamless With NVIDIA BioNeMo 3/19/2025

    Sapio Sciences, the science-aware lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform.

  10. Valo Health And nference Announce Long-Term Partnership To Accelerate Human-Centric Drug Discovery And Development 3/18/2025

    Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced a multi-year collaboration with nference, a company dedicated to transforming healthcare by making biomedical knowledge computable.